Andrew Hedin is a Bessemer Venture Partners investor who bridges biotech and mainstream tech by connecting healthcare-native founders with software and consumer-technology founders across the portfolio, arguing that teams with both drug-development expertise and AI/ML skills will win in drug discovery and clinical trials. His background includes pre-clinical neuroscience research and working in a psychology lab for adolescents with anxiety and depression before switching from medicine to healthcare investing, giving him unusually direct exposure to patient psychology and brain science for a venture investor. Andrew Hedin is a Bessemer Venture Partners investor who bridges biotech and mainstream tech by connecting healthcare-native founders with software and consumer-technology founders across the portfolio, arguing that teams with both drug-development expertise and AI/ML skills will win in drug discovery and clinical trials. His background includes pre-clinical neuroscience research and working in a psychology lab for adolescents with anxiety and depression before switching from medicine to healthcare investing, giving him unusually direct exposure to patient psychology and brain science for a venture investor.